16 5 0 50 100 PEACHTREE (overall, n=64) PEACHTREE (US+Israel, n=40) 98 PEAK and PINNACLE – Key question: how do the APEX data educate the probability of success of PEAK and PINNACLE? The APEX data provide confidence in the probability of success of PEAK and PINNACLE, based on the predicate study PEACHTREE 80 25 0 50 100 PEAK eligible (n=10) PINNACLE eligible (n=8) APEX 1 patients that would meet criteria for PEAK or PINNACLE Week 12 completers Proportion of patients (%) PEACHTREE 2,3 patients treated with sham ≥15-letter gainers APEX 1 patients that would meet criteria for PINNACLE Week 12 completers KSI-101 5 mg and 10 mg pooled PEACHTREE 2 patients treated with sham Proportion of patients (%) 0 0 50 100 PINNACLE eligible (n=8) ≥15-letter losers Rescue medication over 24 weeks 72 0 50 100 PEACHTREE receiving rescue medication (overall, n=64) Improving vision Preventing vision loss Cross-trial assessments should be interpreted with caution due to various limitations 1. Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes only patients in the per protocol set that meet all the inclusion and exclusion criteria. Excludes one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). Includes all data available by the 14-Jul-25 reporting date. 2. Yeh S, et al. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ophthalmology. 2020 Jul;127(7):948-955 3. Xipere FDA Center for Drug Evaluation and Research Biologics Licensing Application Statistical Review. Application number 211950Orig1s000